Literature DB >> 9627952

[Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature].

G Riemekasten1, H Jepsen, G R Burmester, F Hiepe.   

Abstract

A 57-years old female patient with systemic sclerosis underwent a prolonged intravenous therapy during 21 consecutive days with iloprost, a stable analogue of prostacyclin. Beginning with 0.5 ng/ kg/minute the dose was increased every 2 days up to 2 ng/kg/minute. At the end of follow up, Iloprost was shown to enhance the perfusion of the finger and to improve pulmonary-function tests including the diffusion-capacity. Furthermore, the Erythrocyte Sedimentation Rate and the C-reactive protein decreased. The case report shows the necessity of a controlled study of prolonged iloprost therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9627952     DOI: 10.1007/s003930050070

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  8 in total

Review 1.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 2.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

Review 3.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

4.  [Primary and secondary Raynaud's phenomenon].

Authors:  J H W Distler
Journal:  Z Rheumatol       Date:  2008-05       Impact factor: 1.372

Review 5.  [Therapy of systemic sclerosis].

Authors:  M Meurer; P Rehberger
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

Review 6.  [Evidence-based therapy of Raynaud's syndrome].

Authors:  M Distler; J Distler; A Ciurea; D Kyburz; U Müller-Ladner; K Reich; O Distler
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

7.  [Treatment of therapy-resistant acral ulcers with iloprost].

Authors:  S von Schmiedeberg; S Artik; T Assmann; M Megahed; T Ruzicka
Journal:  Hautarzt       Date:  2004-12       Impact factor: 0.751

Review 8.  [Iloprost therapy in systemic sclerosis].

Authors:  G Bali; E Aberer
Journal:  Hautarzt       Date:  2003-09       Impact factor: 0.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.